Abstract |
Interleukin-2 (IL-2) is a highly effective anticancer drug if it is applied locally for 5 consecutive days. In most cases this requires 5 invasive treatments, which is not usually acceptable for either the patient or the clinician. For this reason we have developed dextran-based hydrogels from which the required amount of encapsulated IL-2 (1-4 x 10(6) IU of IL-2) is gradually released during 5-10 days. Initially IL-2-containing macroscopic cylinder-shaped gels (implants), and later IL-2-containing injectable microspheres, were developed. These preparations were characterized in vitro, and the therapeutic activity was tested in DBA/2 mice with SL2 lymphosarcoma. The therapy was given to mice with a large and extensively metastasized tumor load (at least 5% of the body weight). If 1-4 x 10(6) IU of IL-2 was slowly released from the hydrogels over a period of 5-10 days, the therapeutic effects were very good and comparable to the effects of free IL-2 injections for 5 consecutive days. In conclusion, dextran-based hydrogels are promising systems for the controlled release of IL-2.
|
Authors | Cornelis J De Groot, Jenny A Cadée, Jan-Willem Koten, Wim E Hennink, Willem Den Otter |
Journal | International journal of cancer
(Int J Cancer)
Vol. 98
Issue 1
Pg. 134-40
(Mar 01 2002)
ISSN: 0020-7136 [Print] United States |
PMID | 11857397
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2001 Wiley-Liss, Inc. |
Chemical References |
- Dextrans
- Hydrogels
- Interleukin-2
- Methacrylates
- hydroxyethyl methacrylate
|
Topics |
- Animals
- Dextrans
(administration & dosage)
- Female
- Hydrogels
- Interleukin-2
(administration & dosage)
- Methacrylates
(administration & dosage)
- Mice
- Mice, Inbred DBA
- Microspheres
- Neoplasms, Experimental
(pathology, therapy)
|